ArriVent BioPharma, Inc. (NASDAQ:AVBP)
| Market Cap | 658.26M-24.1% |
| Revenue (ttm) | 0 |
| Net Income | -163.74M-19.5% |
| EPS | -3.68+8.5% |
| Shares Out | 49.31M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,238,237 |
| Open | 14.89 |
| Previous Close | 14.87 |
| Day's Range | 13.26 - 14.89 |
| 52-Week Range | 11.36 - 35.83 |
| Beta | 1.35 |
| Analysts | Buy |
| Price Target | 25.00(+87.27%) |
| Earnings Date | Nov 16, 2026 |
Insiders here have filed 5 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About AVBP
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Analyst consensus
7 firms rating AVBP in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Nov 16, 2026Earnings report
Ask Barron about AVBP
$AVBP stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in AVBP holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by AVBP's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
AVBP Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New AVBP patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to AVBP from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in AVBP
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $45.06M |
| XBIState Street SPDR S&P Biotech ETF | $15.31M |
| VXFVanguard Extended Market ETF | $14.22M |
| IWMiShares Russell 2000 ETF | $14.19M |
| VTWOVanguard Russell 2000 ETF | $6.68M |
| IWOiShares Russell 2000 Growth ETF | $5.26M |
Estimated from each fund’s disclosed top holdings × AUM
AVBP Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from AVBP’s recent data — informational, not investment advice
What’s Behind the Score
News check: ARR-217 Phase 1 data shows encouraging 44.8% response rate in colorectal cancer; publication supports pipeline but news lacks major catalysts or analyst upgrades.